Celldex has revealed positive data from the ongoing Phase I study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis. 

These pathways are mast cell depletion via stem cell factor (SCF) starvation and neutralisation of the alarmin thymic stromal lymphopoietin (TSLP).  

CDX-622 was well tolerated, exhibited a good pharmacokinetic profile and induced rapid and sustained reductions in serum tryptase, indicative of mast cell inhibition and depletion.  

“Celldex continues to lead the field in therapeutic targeting of mast cells, presenting promising data today from the first stem cell factor neutralising antibody to be studied in humans,” said Tibor Keler, Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “Combining this unique approach of mast cell depletion with the blockade of a validated and critical inflammation pathway driven by TSLP could potentially deliver profound clinical benefit for patients with inflammatory and fibrotic disorders where both mast cells and TSLP play a pathogenic role.” 

Key presentation highlights: 

  • CDX-622 potently neutralises TSLP and soluble SCF and leads to mast cell reduction in preclinical models. 
  • CDX-622 preferentially inhibits the soluble form of SCF over the membrane form, which may lead to differential impact on KIT-dependent processes. 
  • In a GLP toxicology study, the No-Observed-Adverse-Effect-Level (NOAEL) was the highest dose level tested (75 mg/kg) and led to profound mast cell depletion in the tissues. 
  • In healthy participants, CDX-622 was well tolerated with no dose limiting toxicities, serious adverse events, or infusion reactions and no emergent events related to systemic KIT inhibition. 
  • CDX-622 exhibited mAb-like pharmacokinetics (serum half-life of approximately 18 days at 9 mg/kg) without any evidence of antidrug antibodies (ADA). 
  • A single dose of CDX-622 resulted in a rapid and sustained decrease (~50%) in circulating tryptase consistent with systemic mast cell inhibition and depletion.

Diana Turner, Deputy Editor, DDW